格隆汇3月6日丨心通医疗-B(02160.HK)公告,根据对集团截至2024年12月31日止年度未经审核管理账目的初步审阅及对董事会目前可得最新资料的评估,集团预期报告期录得净亏损约人民币3000万元至人民币6000万元,较截至2023年12月31日止年度减少约87%至94%。该等减少主要是由于:1)公司的经导管主动脉瓣膜植入术产品Vita Flow®及VitaFlow Liberty®和...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.